Literature DB >> 33911278

It's time to invite more people to join clinical trials.

.   

Abstract

Entities:  

Keywords:  Cancer; Epidemiology; Health care

Mesh：

Year:  2021        PMID： 33911278     DOI： 10.1038/d41586-021-01099-4

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  2 in total

1.  Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Authors:  Seung Tae Kim; Simon A Smith; Peter Mortimer; Arsene-Bienvenu Loembé; Heejin Cho; Kyoung-Mee Kim; Claire Smith; Sophie Willis; Itziar Irurzun-Arana; Alienor Berges; Jung Yong Hong; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Iwanka Kozarewa; Andrew J Pierce; Emma Dean; Jeeyun Lee
Journal:  Clin Cancer Res       Date:  2021-05-11       Impact factor: 12.531

2.  Evaluating eligibility criteria of oncology trials using real-world data and AI.

Authors:  Ruishan Liu; Shemra Rizzo; Samuel Whipple; Navdeep Pal; Arturo Lopez Pineda; Michael Lu; Brandon Arnieri; Ying Lu; William Capra; Ryan Copping; James Zou
Journal:  Nature       Date:  2021-04-07       Impact factor: 69.504
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.